Segment 5 - Future Directions

A phase 2 trial demonstrated substantial weight loss with the long-acting peptide–antibody conjugate, as well as other cardiometabolic improvements.

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

The guidelines highlight the need for lifelong obesity management, early diagnosis, comorbidity prevention, and patient-centered care.

Experts discuss how topical therapies effectively manage atopic dermatitis in pediatric patients, enhancing outcomes and addressing unique challenges.

Within the same physician groups, 2-sided risk in Medicare Advantage (MA) was associated with higher quality and lower utilization for dually eligible beneficiaries compared with fee-for-service MA and traditional Medicare.

Phase 3 OCEANIC-STROKE data show how asundexian offers a potential new secondary stroke prevention option.